Multiple Myeloma Trial Of Orally Administered Salmonella-Based Survivin Vaccine (MAPSS) (H-42712)
Multiple Myeloma Trial Of Orally Administered Salmonella-Based Survivin Vaccine (MAPSS)
Multiple myeloma patients will receive a cancer vaccine called TXSVN that has been derived from the bacteria Salmonella. TXSVN is a weakened form of a live vaccine strain of the Salmonella bacteria (also known as the CVD908ssb strain) that has been genetically modified in the laboratory to produce a protein known as Survivin that stimulates an immune response in the body to the Survivin tumor antigen. CVD908ssb has been administered to over 80 healthy donors as a Salmonella vaccine in reported clinical trials. This trial intends to explore administration of this vaccine at a lower dose than what was tested in healthy individuals.
Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90 percent of myeloma cancer cells have been shown to possess large quantities of Survivin.
TXSVN may activate the immune system which is your body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.
TXSVN, the modified strain of CVD908ssb has not been tested in humans to this date. TXSVN is an investigational product not approved by the U.S. Food and Drug Administration.
The purpose of this study is to find the largest safe dose of TXSVN, to learn what the side effects are, and to see whether this therapy might help participants with multiple myeloma.
Age requirements: 18 years and older
More information about this study can be found on clinicaltrials.gov.
NCT#/ClinicalTrials.gov ID: 0376229